Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: an open-label, multicenter, randomized controlled trial.

ABSTRACT:

Background

Studies in murine models suggested that platelet desialylation was an important mechanism of thrombocytopenia during sepsis.

Methods

First, we performed a prospective, multicenter, observational study that enrolled septic patients with or without thrombocytopenia to determine the association between platelet desialylation and thrombocytopenia in patients with sepsis, severe sepsis, and septic shock. Gender- and age-matched healthy adults were selected as normal controls in analysis of the platelet desialylation levels (study I). Next, we conducted an open-label randomized controlled trial (RCT) in which the patients who had severe sepsis with thrombocytopenia (platelet counts ≤50 × 10⁹/L) were randomly assigned to receive antimicrobial therapy alone (co

SUBMITTER: Li MF 

PROVIDER: S-EPMC5426054 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature